Eron Kelly

Eron Kelly, CEO of ConcertAI, and Shaalan Beg, MD, chief medical officer, oncology, ConcertAI, discuss how artificial intelligence (AI) can accelerate clinical trial design, patient identification, and site selection while maintaining trust in clinical data.

AI tools that extract information from unstructured medical records could help oncology practices identify eligible clinical trial patients, surface care gaps, and compare treatment outcomes across real-world cohorts, according to Shaalan Beg and Eron Kelly of ConcertAI.

ConcertAI executives discussed how the company's integration of CancerLinQ has expanded the platform beyond quality reporting, using artificial intelligence to deliver faster clinical insights, improve trial matching, and support oncology practices with real-time data.